Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter to healthcare professionals: Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and r
Source: Royal Pharmaceutical Society News - Category: Drugs & Pharmacology Source Type: news